GH Research PLC(GHRS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

GHRS GH Research PLC

Post-Market Trading 09-19 18:33:43 EDT

7.80

-0.19

-2.38%

盘后7.80

+0.000.00%

16:00 EDT

High8.50	Low7.57	Vol52.04K
Open8.07	D1 Closing7.99	Amplitude11.64%
Mkt Cap405.82M	Tradable Cap50.58M	Total Shares52.03M
T/O413.88K	T/O Rate0.80%	Tradable Shares6.48M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"GHRS","market":"US","secType":"STK","nameCN":"GH Research PLC","latestPrice":7.8,"timestamp":1726776000000,"preClose":7.99,"halted":0,"volume":52044,"hourTrading":{"tag":"盘后","latestPrice":7.8,"preClose":7.8,"latestTime":"16:00 EDT","volume":143,"amount":1115.3999999999999,"timestamp":1726776001926},"delay":0,"floatShares":6484345,"shares":52028145,"eps":-0.674028,"marketStatus":"Post-Market Trading","change":-0.19,"latestTime":"09-19 18:33:43 EDT","open":8.07,"high":8.5,"low":7.57,"amount":413880.1171,"amplitude":0.116395,"askPrice":12.67,"askSize":24,"bidPrice":7.18,"bidSize":4,"shortable":3,"etf":0,"ttmEps":-0.674028,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1726790400000},"marketStatusCode":4,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":7.99,"postHourTrading":{"tag":"盘后","latestPrice":7.8,"preClose":7.8,"latestTime":"16:00 EDT","volume":143,"amount":1115.3999999999999,"timestamp":1726776001926},"volumeRatio":1.593158,"impliedVol":0.5754,"impliedVolPercentile":0.0826},"requestUrl":"/m/hq/s/GHRS","defaultTab":"news","newsList":[{"id":"2468873011","title":"GH Research Engages Investors at Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2468873011","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468873011?lang=en_us&edition=fundamental","pubTime":"2024-09-17 05:27","pubTimestamp":1726522039,"startTime":"0","endTime":"0","summary":"GH Research (GHRS) has released an update. GH Research PLC has announced their participation in the upcoming Cantor Global Healthcare Conference, s...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gh-research-engages-investors-at-healthcare-conference?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gh-research-engages-investors-at-healthcare-conference?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4196","BK4588","ISBC","BK4211","GHRS","BK4539","BK4007","GH","BK4551","BK4585","BK4137","BK4535","HCSG"],"gpt_icon":0},{"id":"2466146641","title":"GH Research to Engage at Global Investment Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2466146641","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466146641?lang=en_us&edition=fundamental","pubTime":"2024-09-10 05:27","pubTimestamp":1725917243,"startTime":"0","endTime":"0","summary":"GH Research (GHRS) has released an update. GH Research PLC, an Ireland-based company, has announced its participation in the upcoming H.C. Wainwrig...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gh-research-to-engage-at-global-investment-conference?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gh-research-to-engage-at-global-investment-conference?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4551","BK4007","BK4196","BK4539","BK4588","GH","BK4535","BK4585","GHRS"],"gpt_icon":0},{"id":"2466037116","title":"GH Research (GHRS) Moves to Buy: Rationale Behind the Upgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=2466037116","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466037116?lang=en_us&edition=fundamental","pubTime":"2024-09-10 00:00","pubTimestamp":1725897610,"startTime":"0","endTime":"0","summary":"GH Research PLC  could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 . This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Since a changing earnings picture is a powerful factor influencing near-term stock price movements, the Zacks rating system is very useful for individual investors. They may find it difficult to make decisions based on rating upgrades by Wall Street analysts, as these are mostly driven by subjective factors that are hard to see and measure in real time.As such, the Zacks rating upgrade for GH Research is essentially a positive comment on its earnings outlook that could have a favorable impact on its stock pric","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/I67vygGrP1BjgOjVx.apeA--~B/aD03Mjg7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/b9775f315e7b6c4ada6e36d0048a929a","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/I67vygGrP1BjgOjVx.apeA--~B/aD03Mjg7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/b9775f315e7b6c4ada6e36d0048a929a"],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gh-research-ghrs-moves-buy-160010209.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GH","GHRS"],"gpt_icon":0},{"id":"2466191906","title":"After Plunging -18.19% in 4 Weeks, Here's Why the Trend Might Reverse for GH Research (GHRS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2466191906","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466191906?lang=en_us&edition=fundamental","pubTime":"2024-09-09 21:35","pubTimestamp":1725888906,"startTime":"0","endTime":"0","summary":"GH Research PLC  has been beaten down lately with too much selling pressure. While the stock has lost 18.2% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.We use Relative Strength Index , one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that measures the speed and change of price movements.RSI oscillates between zero and 100. Usually, a stock is considered oversold when its RSI reading falls below 30.Technically, every stock oscillates between being overbought and oversold irrespective of the quality of their fundamentals. And the beauty of RSI is that it helps you quickly and easily check if a stock's price is reaching a point of reversal.The RSI reading of 22.34 for GHRS is an indication that the heavy selling could be in the process of exhausting itself, so th","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/UYup8AGIrn99rMsHiTllqA--~B/aD04NzY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/d0d4ab152198da2f423d92da8a7d22ee","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/UYup8AGIrn99rMsHiTllqA--~B/aD04NzY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/d0d4ab152198da2f423d92da8a7d22ee"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/plunging-18-19-4-weeks-133506058.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4535","BK4150","BK4551","BK4588","BK4539","BK4196","BK4585","RSI","BK4007","GH","GHRS"],"gpt_icon":0},{"id":"2466904658","title":"Weekly Roundup on the Cannabis Sector & Psychedelic Sector","url":"https://stock-news.laohu8.com/highlight/detail?id=2466904658","media":"Market Exclusive","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466904658?lang=en_us&edition=fundamental","pubTime":"2024-09-09 09:14","pubTimestamp":1725844441,"startTime":"0","endTime":"0","summary":"Organigram secured CA$41.5 million in second investment tranche from British American Tobacco.Jushi Holdings filed for CA$350 million shelf offering.Massachusetts social equity advocates are demanding investigation into Ascend Wellness over cannabis license violations.Awakn filed new patent for ‘promising’ psychedelic compounds to treat PTSD.GH Research faced continued losses in the second quarter, amid efforts to lift FDA hold on GH001.Below is a weekly roundup of what happened this week in the cannabis and psychedelic sectors. In this ever-evolving landscape, we explore the major developments and groundbreaking initiatives happening among companies operating in these industries; from advancements in medical research, therapeutic applications to shifts in legal frameworks and current market trends.According to the company, the purpose of this move is to maintain financial flexibility and position Jushi to capitalize on potential regulatory changes in the U.S. cannabis market and pursu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/weekly-roundup-cannabis-sector-psychedelic-011401974.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","BK4588","BK4075","BTI","BK4007","BK4539","OGI","GHRS","BK4557"],"gpt_icon":0},{"id":"2465795435","title":"GH Research Price Target Maintained With a $40.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2465795435","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2465795435?lang=en_us&edition=fundamental","pubTime":"2024-09-06 02:46","pubTimestamp":1725561960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GHRS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 05, 2024 14:46 ET (18:46 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH","GHRS"],"gpt_icon":0},{"id":"2465394544","title":"Irish Biotech Firm GH Research Sees Cash Decline in Q2, Advances Psychedelic Drug Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2465394544","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2465394544?lang=en_us&edition=fundamental","pubTime":"2024-09-05 21:22","pubTimestamp":1725542520,"startTime":"0","endTime":"0","summary":"Irish psychedelic biotech firm GH Research PLC (NASDAQ: GHRS) reported on Tuesday financial results for the second quarter ended June 30, 2024. Cash, cash equivalents, other financial assets and marketable securities were $204.5 million as of June 30, 2024, compared to cash, cash equivalents, other financial assets and marketable securities of $222.7 million as of December 31, 2023.The net loss was $10.4 million, or $0.20 loss per share, for the quarter that ended June 30, 2024, compared to the $7.7 million or $0.15 loss per share for the same quarter in 2023. The Dublin-based company also provided an update on its DMT-related drugs that are currently undergoing clinical trials.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/cannabis/24/09/40730912/irish-biotech-firm-gh-research-sees-cash-decline-in-q2-advances-psychedelic-drug-trials","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4023","BK4535","PD","BK4551","BK4588","LU1169589451.USD","BK4539","BK4196","BK4585","BK4007","GH","GHRS","LU1169590202.USD"],"gpt_icon":0},{"id":"2465834225","title":"GH Research Price Target Maintained With a $39.00/Share by JMP Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2465834225","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2465834225?lang=en_us&edition=fundamental","pubTime":"2024-09-05 00:31","pubTimestamp":1725467460,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GHRS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 04, 2024 12:31 ET (16:31 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GHRS","GH","JMP"],"gpt_icon":0},{"id":"2464357300","title":"GH Research to Connect at Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2464357300","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2464357300?lang=en_us&edition=fundamental","pubTime":"2024-09-04 05:27","pubTimestamp":1725398861,"startTime":"0","endTime":"0","summary":"GH Research (GHRS) has released an update. GH Research PLC, an Ireland-based company, has announced its participation in the upcoming Morgan Stanle...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gh-research-to-connect-at-global-healthcare-conference?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gh-research-to-connect-at-global-healthcare-conference?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4551","BK4196","BK4504","IE00BZ1G4Q59.USD","LU1720051108.HKD","BK4588","LU1548497426.USD","BK4535","LU0267386448.USD","LU1720051017.SGD","BK4534","BK4127","GHRS","LU0320765646.SGD","LU1074936037.SGD","LU0106831901.USD","LU1989772923.USD","IE00BKVL7J92.USD","BK4581","LU0971096721.USD","LU0314104364.USD","LU0098860793.USD","BK4585","LU1668664300.SGD","LU2357305700.SGD","BK4539","GH","LU1989772840.SGD","LU0225283273.USD","HCSG","LU1162221912.USD","LU1363072403.SGD","BK4007","BK4137"],"gpt_icon":0},{"id":"2464836872","title":"GH Research Names Velichka Valcheva as CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2464836872","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2464836872?lang=en_us&edition=fundamental","pubTime":"2024-09-03 19:26","pubTimestamp":1725362760,"startTime":"0","endTime":"0","summary":"GH Research on Tuesday said it promoted Velichka Valcheva to chief executive officer, replacing co-founder Theis Terwey.The clinical-stage biopharmaceutical company focused on the treatment of psychiatric and neurological disorders said Valcheva joined the company in August 2023 and served as the Chief Medical Officer since February 2024.Valcheva has more than 20 years of experience in several leadership roles in the pharmaceutical and biotech industries, the company added.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","BK4539","BK4588","BK4535","GHRS","BK4007","BK4551","BK4585","GH"],"gpt_icon":0},{"id":"2464871780","title":"BRIEF-GH Research Appoints Velichka Valcheva As CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2464871780","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2464871780?lang=en_us&edition=fundamental","pubTime":"2024-09-03 19:09","pubTimestamp":1725361751,"startTime":"0","endTime":"0","summary":"Sept 3 (Reuters) - GH Research PLC   :   * GH RESEARCH ANNOUNCES APPOINTMENT OF DR. VELICHKA “VILLY” VALCHEVA TO CHIEF EXECUTIVE OFFICERSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4196","BK4588","BK4585","BK4007","GH","GHRS","BK4539","BK4551"],"gpt_icon":0},{"id":"2464871095","title":"GH Research Q2 2024 GAAP EPADS $(0.20) Beats $(0.23) Estimate, Cash Balance Of $204.5M","url":"https://stock-news.laohu8.com/highlight/detail?id=2464871095","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2464871095?lang=en_us&edition=fundamental","pubTime":"2024-09-03 19:09","pubTimestamp":1725361742,"startTime":"0","endTime":"0","summary":"GH Research Q2 2024 GAAP EPADS $(0.20) Beats $(0.23) Estimate, Cash Balance Of $204.5M","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/09/40683298/gh-research-q2-2024-gaap-epads-0-20-beats-0-23-estimate-cash-balance-of-204-5m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","BK4588","BK4535","BK4007","BK4585","GHRS","BK4539","BK4551","GH"],"gpt_icon":0},{"id":"2464087194","title":"Press Release: GH Research Reports Second Quarter 2024 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2464087194","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2464087194?lang=en_us&edition=fundamental","pubTime":"2024-09-03 19:05","pubTimestamp":1725361500,"startTime":"0","endTime":"0","summary":"-- Phase 2b clinical trial of GH001 in patients with treatment-resistant. depression on track for expected completion of double-blind phase in Q3. 2024 and expected completion of 6-month open-label extension phase in Q1. DUBLIN, Sept. 03, 2024  -- GH Research PLC , a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the second quarter ended June 30, 2024, and provided updates on its business.We announced today, in a separate press release, the promotion of Dr. Velichka \"Villy\" Valcheva, MD, MSc. to Chief Executive Officer of the Company. Dr. Valcheva succeeds PD Dr. med. Theis Terwey, co-founder of GH Research.We previously announced our submission of a clinical trial application for a Phase 1 clinical pharmacology trial in Europe to evaluate our proprietary aerosol delivery device for administration of GH001 in healthy volunteers . This trial is designed to support bridging t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1169590202.USD","BK4121","BK4551","GH","GHRS","BK4007","BK4539","BK4181","BK4585","LU1169589451.USD","BK4588","BK4218","BK4530","BK4561","BK4535","BK4196","PPD","PD","BK4023","PK"],"gpt_icon":0},{"id":"2464707879","title":"GH Research Announces Appointment of DR. Velichka “Villy” Valcheva to Chief Executive Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2464707879","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2464707879?lang=en_us&edition=fundamental","pubTime":"2024-09-03 19:00","pubTimestamp":1725361206,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240903:nTUA3KF8JW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GHRS","BK4539","BK4007"],"gpt_icon":0},{"id":"2461452753","title":"Trials for psychedelic drug candidate for PTSD under scrutiny by FDA - report","url":"https://stock-news.laohu8.com/highlight/detail?id=2461452753","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2461452753?lang=en_us&edition=fundamental","pubTime":"2024-08-24 06:34","pubTimestamp":1724452452,"startTime":"0","endTime":"0","summary":"The U.S. FDA has been conducting interviews with several individuals familiar with clinical trials conducted by Lykos Therapeutics for its rejected MDMA-based PTSD therapy as it investigates potential improprieties.  The Wall Street Journal reported that at four individuals have been interviewed about the possibility some side effects -- including suicidal thoughts -- were not reported.  The newspaper noted that one person interviewed was asked about the techniques used in giving the therapy, called midomafetamine. Earlier in August, the FDA issued a Complete Response Letter to Lykos on the drug and asked the company to conduct an additional trial. Less than a week later, Lykos said it would lay off 75% of its workforce. Publicly traded psychedelic-focused drug developers include Mind Medicine , Atai Life Sciences , COMPASS Pathways , Cybin , and GH Research . Nano-caps include 180 Life Sciences , Enveric Biosciences , Seelos Therapeutics , SciSparc , Bright Minds Biosciences , and Cle","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1286971235/image_1286971235.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1286971235/image_1286971235.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4143520-trials-psychedlic-drug-candidate-ptsd-under-scrutiny-fda","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["QQQ","BK4547","ENVB","BK4139","SQQQ","ATNF","CYBN","PSQ","MNQmain","GHRS","BK4168","ATAI","SEEL","CMPS","BK4539","QID","BK4007","QLD",".IXIC","MNMD","NQmain","TQQQ","SPRC","CMND","DRUG"],"gpt_icon":1},{"id":"2459401548","title":"Lykos laying off 75% of workforce following FDA rejection of psychedelic drug for PTSD","url":"https://stock-news.laohu8.com/highlight/detail?id=2459401548","media":"seekingalpha","labels":["Policy And Regulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459401548?lang=en_us&edition=fundamental","pubTime":"2024-08-16 03:02","pubTimestamp":1723748562,"startTime":"0","endTime":"0","summary":"Lykos Therapeutics, the privately held psychedelic drug developer, is letting go of 75% of its employees following the U.S. FDA's decision earlier in August to reject its application for an MDMA-based drug to treat PTSD. In addition, Rick Doblin, the co-founder of the Multidisciplinary Association for Psychedelic Studies which incubated Lykos, is stepping down from the company's board.  David Hough, a former R&D exec with Johnson & Johnson Innovative Medicine, has been brought on to oversee discussions with the agency and clinical development going forward. Lykos has also formed an independent advisory board to support management through the midomafetamine resubmission process. Publicly traded psychedelic-focused drug developers include Mind Medicine , Atai Life Sciences , COMPASS Pathways , Cybin , and GH Research . Nano-caps include 180 Life Sciences , Enveric Biosciences , Seelos Therapeutics , SciSparc , Bright Minds Biosciences , and Clearmind Medicine .","market":"fut","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/882024294/image_882024294.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/882024294/image_882024294.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4140729-lykos-laying-off-75-workforce-following-fda-rejection-psychedelic-drug-ptsd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4139","DRUG","SEEL","GHRS","TQQQ","PSQ","MNMD","BK4168","NQmain","QID","QLD","ENVB","BK4539",".IXIC","ATAI","SQQQ","CMND","MNQmain","BK4007","ATNF","CYBN","CMPS","SPRC","BK4547"],"gpt_icon":1},{"id":"2458386359","title":"Medical journal retracts three articles related to MDMA for PTSD","url":"https://stock-news.laohu8.com/highlight/detail?id=2458386359","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2458386359?lang=en_us&edition=fundamental","pubTime":"2024-08-12 23:50","pubTimestamp":1723477821,"startTime":"0","endTime":"0","summary":"The journal Psychopharmacology on Aug. 10 retracted three articles related to the use of MDMA for PTSD, the day after the U.S. FDA rejected the use of the psychedlic drug for the condition. Scientists","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1401915065/image_1401915065.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1401915065/image_1401915065.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4138677-medical-journal-retracts-three-articles-related-mdma-ptsd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["MNQmain","SEEL","QQQ","BK4585","PSQ","ATNF",".IXIC","BK4007","ATAI","CMND","BK4139","NQmain","BK4539","QLD","SPR","DRUG","QID","CMPS","BK4547","SQQQ","BK4187","MNMD","BK4588","ENVB","GHRS","TQQQ"],"gpt_icon":0},{"id":"2458547725","title":"Psychedelic drug developers face setback as ecstasy-based drug rejected by FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2458547725","media":"seekingalpha","labels":["Policy And Regulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2458547725?lang=en_us&edition=fundamental","pubTime":"2024-08-10 06:04","pubTimestamp":1723241074,"startTime":"0","endTime":"0","summary":"The U.S. FDA has rejected privately-held Lykos Therapeutics' drug related to the psychedelic MDMA, also known as ecstasy, for PTSD. The issuing of a Complete Response Letter is not that surprising con","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/508919350/image_508919350.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/508919350/image_508919350.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4138378-psychedlic-drug-developers-setback-ecstasy-based-drug-rejected-fda","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["MNQmain","BK4547","TQQQ","BK4139","CMND","PSQ","SEEL","ATNF","MNMD","NQmain","ENVB","BK4539","DRUG","CMPS","SQQQ",".IXIC","SPRC","GHRS","QLD","ATAI","QID","BK4007"],"gpt_icon":1},{"id":"2455718062","title":"GH Research Price Target Maintained With a $40.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2455718062","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2455718062?lang=en_us&edition=fundamental","pubTime":"2024-07-31 20:18","pubTimestamp":1722428280,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GHRS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 31, 2024 08:18 ET (12:18 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH","GHRS"],"gpt_icon":0},{"id":"2449391274","title":"3 Psychedelic Stocks to Ride to the Moon and Beyond","url":"https://stock-news.laohu8.com/highlight/detail?id=2449391274","media":"InvestorPlace","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2449391274?lang=en_us&edition=fundamental","pubTime":"2024-07-06 19:21","pubTimestamp":1720264860,"startTime":"0","endTime":"0","summary":"Psychedelic stocks are a hot, trending area of investment as the FDA continues to weigh regulatory considerations that will open the market.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://investorplace.com/2024/07/3-psychedelic-stocks-to-ride-to-the-moon-and-beyond/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investorplace_stock_picks","symbols":["BK4178","BK4588","BK4585","BK4007","MNMD","GHRS","BK4547","ATAI","BK4539"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ghres.com","stockEarnings":[{"period":"1week","weight":-0.0184},{"period":"1month","weight":-0.2441},{"period":"3month","weight":-0.313},{"period":"6month","weight":-0.2581},{"period":"1year","weight":-0.2295},{"period":"ytd","weight":0.3776}],"compareEarnings":[{"period":"1week","weight":0.0126},{"period":"1month","weight":0.0032},{"period":"3month","weight":0.0263},{"period":"6month","weight":0.0771},{"period":"1year","weight":0.2681},{"period":"ytd","weight":0.1811}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies to treat psychiatric and neurological disorders. The company develops 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable mebufotenin product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an intravenous mebufotenin product candidate; and GH003, an intranasal mebufotenin product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.016317},{"month":2,"riseRate":0.666667,"avgChangeRate":0.073102},{"month":3,"riseRate":0.666667,"avgChangeRate":0.047655},{"month":4,"riseRate":0.666667,"avgChangeRate":-0.041493},{"month":5,"riseRate":0.666667,"avgChangeRate":0.102368},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.039027},{"month":7,"riseRate":0.75,"avgChangeRate":0.049146},{"month":8,"riseRate":0.5,"avgChangeRate":0.039665},{"month":9,"riseRate":0.25,"avgChangeRate":-0.134414},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.083079},{"month":11,"riseRate":0.666667,"avgChangeRate":-0.008629},{"month":12,"riseRate":0,"avgChangeRate":-0.100218}],"exchange":"NASDAQ","name":"GH Research PLC","nameEN":"GH Research PLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.26.4","shortVersion":"4.26.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"GH Research PLC(GHRS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest GH Research PLC(GHRS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"GH Research PLC,GHRS,GH Research PLC股票,GH Research PLC股票老虎,GH Research PLC股票老虎国际,GH Research PLC行情,GH Research PLC股票行情,GH Research PLC股价,GH Research PLC股市,GH Research PLC股票价格,GH Research PLC股票交易,GH Research PLC股票购买,GH Research PLC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"GH Research PLC(GHRS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest GH Research PLC(GHRS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}